We conducted an online rating process whereby panellists rated each recommendation from Stage 1 according to three criteria: burden of illness (e.g. prevalence, severity, costs); potential for significant patient benefit (e.g. longevity, quality of life, safety of care); and scope for improvement upon current levels of adherence (e.g. from perceived current low levels or high variations).
One ED Director stressed the importance of adherence to established scopes of practice to recognise that the NP was an independent practitioner who was nevertheless part of a multidisciplinary team.
We therefore limit the scope of this chapter to an examination of adherence in the context of individual outpatient psychotherapy delivered to adult populations, with particular attention paid to evidence-based, cognitive-behavioral treatments.
The scope of the study is patient adherence to medical treatment in the cure and care sector.
It is also argued that, because the magnitude of non-adherence and the scope of its effect are high, more health benefits worldwide would result from improving adherence to existing treatments than by developing new medical treatments [ 8].
Assessment of adherence to national guidelines is outside the scope of this article but will be considered separately.
While intake of medications, including prescribed, over the counter, and complementary medicines, was confirmed by practice nurses with patients during data collection, it was beyond the scope of our study to measure medication adherence.
Further studies looking at attendance and adherence should consider carefully the definition and scope of measures selected, as the literature provides no clear consensus on how adherence should be measured.
Outcome measures: Measures of adherence, adherence rates and factors associated with adherence.
Then there is the question of adherence.
Addressing the challenges of adherence.
